Article
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.
Scientific reports - 21 Oct 2013
Zhang Lianhai, Yang Jie, Cai Jie, Song Xiaoming, Deng Jianyun, Huang Xuesong, Chen Dawei, Yang Mengmeng, Wery Jean-Pierre, Li Shuangxi, Wu Aiwen, Li Ziyu, Li Zhongwu, Liu Yiqiang, Chen Yiyou, Li Qixiang, Ji Jiafu
Abstract excerpt
A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.